12.42 -0.38 (-2.96%)
MYL
Stock Details
Last Trade:12.42 Change:-0.38 (-2.96%) Prev Close:12.80 Open: 12.82 Days Range:12.30 – 12.85 52 Week Range: 5.75 - 14.94 Volume:8059802 P/E: 23.88EPS:0.52
View AllRecent Alerts 07/03/09
Recent Alert on 06/29/09 at 7:46am
Mylan (MYL) Announces Exclusive Collaboration with Biocon to Enter Global Generic Biologics Market
Mylan (MYL) Announces Exclusive Collaboration with Biocon to Enter Global Generic Biologics Market
Mylan Inc. (Nasdaq: MYL) today announced that it has executed a definitive agreement with Biocon Limited, a publicly traded company on the Indian stock exchanges, for an exclusive collaboration on the development, manufacturing, supply and... Read More
Recent Alert on 06/17/09 at 8:06am
Mylan (MYL) Receives FDA Approval for ANDA for Temazepam Capsules USP, 22.5 mg
Mylan (MYL) Receives FDA Approval for ANDA for Temazepam Capsules USP, 22.5 mg
Recent Alert on 06/17/09 at 8:06am
Mylan (MYL) Receives FDA Approval for ANDA for Temazepam Capsules USP, 22.5 mg
Mylan (MYL) Receives FDA Approval for ANDA for Temazepam Capsules USP, 22.5 mg
Recent Alert on 05/29/09 at 8:09am
Mylan (MYL) Receives Tentative FDA Approval for Generic Version of Singulair(R)
Mylan (MYL) Receives Tentative FDA Approval for Generic Version of Singulair(R)
View AllRecent Press Releases
Press Release on 06/30/09 at 12:53pm
PARI LC Plus and PRONEB Ultra Used in Two Perforomist Studies on Improving COPD Therapies
PARI LC Plus and PRONEB Ultra Used in Two Perforomist Studies on Improving COPD Therapies
Press Release on 06/29/09 at 6:30am
Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market
Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market
View AllRecent SEC Filings
No Recent SEC Filings Available